The endocannabinoid system as a target for the treatment of cannabis dependence
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
The endocannabinoid system modulates neurotransmission at inhibitory and excitatory synapses in brain regions relevant to the regulation of pain, emotion, motivation, and cognition. This signaling system is engaged by the active component of cannabis, Δ9-tetrahydrocannabinol (Δ9-THC), which exerts its pharmacological effects by activation of G protein-coupled type-1 (CB1) and type-2 (CB2) cannabinoid receptors. During frequent cannabis use a series of poorly understood neuroplastic changes occur, which lead to the development of dependence. Abstinence in cannabinoid-dependent individuals elicits withdrawal symptoms that promote relapse into drug use, suggesting that pharmacological strategies aimed at alleviating cannabis withdrawal might prevent relapse and reduce dependence. Cannabinoid replacement therapy and CB1 receptor antagonism are two potential treatments for cannabis dependence that are currently under investigation. However, abuse liability and adverse side effects may limit the scope of each of these approaches. A potential alternative stems from the recognition that (i) frequent cannabis use may cause an adaptive downregulation of brain endocannabinoid signaling, and (ii) that genetic traits that favor hyperactivity of the endocannabinoid system in humans may decrease susceptibility to cannabis dependence. These findings suggest in turn that pharmacological agents that elevate brain levels of the endocannabinoid neurotransmitters, anandamide and 2-arachidonoylglycerol (2-AG), might alleviate cannabis withdrawal and dependence. One such agent, the fatty-acid amide hydrolase (FAAH) inhibitor URB597, selectively increases anandamide levels in the brain of rodents and primates. Preclinical studies show that URB597 produces analgesic, anxiolytic-like and antidepressant-like effects in rodents, which are not accompanied by overt signs of abuse liability. In this article, we review evidence suggesting that (i) cannabis influences brain endocannabinoid signaling; and (ii) FAAH inhibitors such as URB597 might offer a possible therapeutic avenue for the treatment of cannabis withdrawal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 1×
“Two endogenous cannabinoid receptor ligands, arachidonoylethanolamide (anandamide) (Devane et al., 1992; Di Marzo et al., 1994) and 2-arachidonoylglycerol (2-AG), have been identified (Mechoulam et al., 1995; Stella et al., 1997; Sugiura et al., 1995).”
Background2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Herkenham, M., Lynn, A., Johnson, M., Melvin, L., de Costa, B., & Rice, K. (1991) · The Journal of Neuroscience · doi:10.1523/jneurosci.11-02-00563.1991 · Cited by 2,159 · cited 3×
“Moderate receptor levels are also present in the basolateral amygdala, hypothalamus, and the periaqueductal gray matter of the midbrain (Glass et al., 1997; Herkenham et al., 1991; Katona et al., 2001; Matsuda et al., 1993).”
BackgroundMolecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125 · cited 3×
“…completed by the activity of fattyacid amide hydrolase (FAAH), a membrane-associated serine hydrolase that belongs to the amidase signature family of enzymes (Cravatt et al., 1996; Désarnaud et al., 1995; Giang and Cravatt, 1997; Hillard et al., 1995; Patricelli et al., 1999; Ueda et al., 1995).”
BackgroundThe molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957 · cited 1×
“The distribution of CB1 receptors in the brain is reflective of the important functions served by the endocannabinoid signaling system in the control of pain, emotion, motivation and cognition (Piomelli, 2003).”
BackgroundSelf-citationWillner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832 · cited 2×
“Hill and colleagues used a 3-week unpredictable stress protocol that included restraint stress, whereas our study was longer, but included less severe stressors such as cage tilting, floor soiling, and food deprivation (Bortolato et al., 2007; Willner, 1997).”
BackgroundThe endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728 · cited 1×
“Experiments with CB1-null mice and CB1 receptor antagonists suggest that removing CB1 activity heightens anxiety- and depression-related behaviors (Alberich Jorda et al., 2002; Haller et al., 2002, 2004; Marsicano et al., 2002; Martin et al., 2002; Uriguen et al., 2004).”
BackgroundNew approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Self-citationEffects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · cited 2×
“…side-effect profile demonstrated by the CB1 antagonist rimonabant in human trials, where anxiety, irritability and depression were among the most frequent adverse events reported (Despres et al., 2005; Gelfand and Cannon, 2006; Pi-Sunyer et al., 2006; Scheen et al., 2006; Van Gaal et al., 2005).”
BackgroundResult
Cited by
Keep off the grass? Cannabis, cognition and addiction
Curran, H. V., Freeman, T. P., Mokrysz, C., Lewis, D. A., Morgan, C. J. A., & Parsons, L. H. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.28 · Cited by 389
Shonesy, B. C., Bluett, R. J., Ramikie, T. S., Báldi, R., Hermanson, D. J., Kingsley, P. J., Marnett, L. J., Winder, D. G., Colbran, R. J., & Patel, S. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.11.001 · Cited by 155
Davis, M. L., Powers, M. B., Handelsman, P., Medina, J. L., Zvolensky, M., & Smits, J. A. J. (2015) · Evaluation & the Health Professions · doi:10.1177/0163278714529970 · Cited by 114
“Importantly, it appears that these withdrawal symptoms are strongly related to the downregulation of brain endocannabinoids resulting from frequent cannabis use (Bortolato et al., 2006, 2007; Clapper et al., 2009; Gobbi et al., 2005).”
BackgroundCrippa, J. A. S., Hallak, J. E. C., Machado-de-Sousa, J. P., Queiroz, R. H. C., Bergamaschi, M., Chagas, M. H. N., & Zuardi, A. W. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12018 · Cited by 101
“Evidence from human and animal studies suggests that chronic cannabis use reduces CB1 receptor activation and that this downregulation is related to tolerance and withdrawal symptoms.(32) Moreover, subjects carrying a genetic variation that reduces the expression and activity of the fatty acid amide hydrolase (FAAH),…”
BackgroundBoileau, I., Mansouri, E., Williams, B., Le Foll, B., Rusjan, P., Mizrahi, R., Tyndale, R. F., Huestis, M. A., Payer, D. E., Wilson, A. A., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.04.012 · Cited by 82
Metadata
- Authors
- Clapper, J. R., Mangieri, R. A., & Piomelli, D.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 56
- Pages
- 235-243
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2165401144
- Cited by
- 92
- References
- 35
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The endocannabinoid system as a target for the treatment of cannabis dependence. https://app.cochat.ai/papers/10.1016/j.neuropharm.2008.07.018
- The paper
- Clapper, J. R., Mangieri, R. A., & Piomelli, D. (2009). The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2008.07.018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.